VN July 2026

Vetnews | Julie 2026 44 « BACK TO CONTENTS A Introduction The South African veterinary market has seen a marked increase in oral health supplements for dogs and cats. These products, typically presented as powders, sprays or feed additives, are marketed as convenient daily solutions to improve oral health, reduce tartar accumulation and, in some instances, to “manage” gingival disease. Their appeal is obvious. They offer a seemingly simple alternative to tooth brushing and professional dental care, both of which require time, compliance and, often, financial commitment from pet owners. For the practising veterinarian, however, these products present a growing challenge. Clients are increasingly aware of them and often arrive with expectations shaped by persuasive and scientifically framed marketing. The language used is frequently sophisticated, invoking concepts such as microbiome modulation, anti-inflammatory pathways and antimicrobial activity. While these concepts are biologically plausible, there is a recurring and important distinction that must be made: plausibility is not the same as proven clinical efficacy. Periodontal disease remains fundamentally a plaque-driven condition. A structured bacterial biofilm adheres to the tooth surface, matures over time and, in the absence of disruption, mineralises into calculus. This process initiates gingival inflammation and ultimately leads to progressive periodontal destruction. The central tenet of effective dental care is therefore the mechanical disruption of this biofilm. Tooth brushing, appropriately designed dental diets and certain validated dental chews all share this fundamental mechanism. Any intervention that does not physically disrupt plaque should be regarded as adjunctive at best and insufficient as a primary therapeutic approach.¹ Many of the currently available dental supplements rely on a relatively small group of recurring ingredients. We evaluated the following four. 1. Brown seaweed (Ascophyllum nodosum) Brown seaweed (Ascophyllum nodosum) is one of the few with moderate supporting evidence in veterinary dentistry. Controlled studies have demonstrated reductions in plaque and calculus accumulation, with effects that appear to be systemic rather than local, possibly mediated through alterations in saliva composition or bacterial adhesion.² An important consideration, often overlooked in clinical discussions, is the issue of dose. While individual product formulations frequently do not disclose inclusion rates, review data indicate that effective dosing in experimental and clinical contexts has varied considerably. Reported regimens include administration as part of the daily diet at relatively high inclusion levels, as well as targeted dosing in the region of approximately 27–50 mg/kg body weight per meal.² These variations reflect differences in formulation, delivery method and study design, and make direct comparisons challenging. The key implication for clinical practice is that dose is not incidental but central to efficacy. Even where an ingredient has demonstrated benefit, the magnitude of that benefit is dependent on achieving an adequate and consistent intake. In the absence of transparent dosing information in commercial products, it becomes difficult, if not impossible, to determine whether a product delivers a biologically meaningful quantity. It is therefore reasonable to regard the dosing ranges described in the literature as indicative of minimum effective exposure levels rather than guarantees of efficacy across all formulations. The mere presence of Ascophyllum nodosum in a product does not ensure that it is included at a level sufficient to replicate the outcomes reported in controlled studies. This underscores a broader principle in evidence-based dentistry: the presence of an active ingredient, without clear information on dose and delivery, does not allow for meaningful extrapolation of clinical efficacy. 2. Sodium hexametaphosphate Sodium hexametaphosphate acts by binding calcium in saliva and thereby reducing the mineralisation of plaque into calculus. This mechanism is well established in dental diets. However, it is important to recognise that such compounds do not remove plaque and do not directly address gingival inflammation. Their role is therefore limited to slowing calculus accumulation and remains dependent on concurrent plaque control. 3. Chlorhexidine Chlorhexidine occupies a unique position in veterinary dentistry as a well-established antimicrobial agent and is often described as the gold standard for chemical plaque control. This designation is supported by extensive human dental literature, most notably the work published in Periodontology 2000, which clearly establishes chlorhexidine digluconate as the benchmark against which other antiplaque agents are measured.³ However, this status requires careful qualification. The evidence base is specifically derived from the use of chlorhexidine digluconate at concentrations typically ranging from 0.12% to 0.2%, delivered as oral rinses, bioadhesive gels or professionally applied solutions.The mere presence of “chlorhexidine” on a product label is therefore insufficient to infer clinical efficacy. Different chlorhexidine salts vary in solubility, bioavailability and retention, and these differences are seldom disclosed. More importantly, the delivery method plays a decisive role. Low-volume oral sprays, which are commonly marketed for convenience, are rapidly diluted by saliva, swallowed and unevenly distributed across oral surfaces. While such formulations may have a transient effect on oral bacterial load and may improve halitosis, they are unlikely to achieve sustained plaque inhibition or exert a meaningful effect on subgingival biofilm. The clinical performance observed in controlled studies cannot simply be extrapolated to these delivery systems. Regulars I Dental Column Dental Supplements in Small Animal Practice: Separating Evidence from Marketing Prof Gerhard Steenkamp, Drs Mareli van de Wetering & Michael Ferreira

RkJQdWJsaXNoZXIy OTc5MDU=